Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions.
about
Glomerular diseases and cancer: evaluation of underlying malignancy.Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.Primary care of the renal transplant patient.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Hypertension in chronic kidney disease: navigating the evidence.ABO-incompatible kidney transplantation in elderly patients over 60 years of age.Age, exclusion criteria, and generalizability of randomized trials enrolling kidney transplant recipients.High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients.Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator.Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study.Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.Pilot study of a pharmaceutical care intervention in an outpatient lung transplant clinic.Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors.Clinical outcomes and management of inflammatory bowel disease in the older patient.Systemic use of non-biologic agents in orofacial diseases: other immunomodulatory agents.Clinical implications of ageing for the management of IBD.Central nervous system syndromes in solid organ transplant recipients.Immunotherapy of Fungal Infections.The investigation of correlation between Iminoral concentration and neurotoxic levels after kidney transplantation.Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients.Systemic exposure to armodafinil and its tolerability in healthy elderly versus young men: an open-label, multiple-dose, parallel-group study.Characteristics of late-onset myasthenia gravis.Is a flavonoid-rich diet with steamer cooking safe during calcineurin inhibitors therapy?A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics
P2860
Q26779686-DE4EE18D-6626-43F4-A5F4-F8C78B47D8F3Q33625213-5D07E2DC-E07C-4278-A298-1796E2A3CF43Q33898744-A3C9AFF8-5EC1-4DC0-869A-B940D3A865E8Q34532546-2FBDCBFE-A2DC-42FF-83AA-B57FEAF938D6Q35071147-015DEC1E-4148-471D-BBD8-1E05A0286151Q36240855-EA118474-F74A-45C0-97E4-02261743437BQ36292023-CB46A5D2-E575-4893-B998-1B3DEFF27D1BQ37135382-164767AD-15A0-4F30-B8F7-D01DF2BD1B7BQ37587285-06469719-476A-4059-9F22-4BBE1DB0CC9DQ37737279-2386BBC8-47EA-44B7-AC5E-2C6E90085370Q37818197-62989596-3F59-4B7A-B456-EAC8D3991BA0Q38002977-DC11990A-D2DB-4C75-BC7B-CB01DA94ACE1Q38027466-B2733017-2CD0-4108-BF8F-D21A35EAA6D2Q38073185-677076A6-EFCE-4C51-A035-C6068A583554Q38136748-7078243D-E2FA-44AA-AE8B-92C5981BC191Q38171926-C96742A7-E674-45B4-AA0B-D24B93201875Q38219391-89B06D9C-0FE7-4668-82FB-AF43CBD538BFQ38635409-2E7E3DF8-A3D7-4591-AB85-61B814CFCFD5Q41172380-7E274423-8B4D-4E3C-8B2F-CBF03C858A41Q41886472-161FFC48-1175-40F9-AA5A-42F82E9B6F5EQ42687882-37ED38A3-2711-47B5-808D-6FF70F3E521CQ48703896-5856A175-1CFC-49A6-8CDC-650C7837DB1AQ50454323-77C51BF3-A1C6-49D7-B05A-79FFFCF2BAFCQ58294605-821C15AF-763D-47C3-A9CA-2B2BDBDCA03B
P2860
Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunotherapy in elderly trans ...... significant drug interactions.
@en
Immunotherapy in elderly trans ...... significant drug interactions.
@nl
type
label
Immunotherapy in elderly trans ...... significant drug interactions.
@en
Immunotherapy in elderly trans ...... significant drug interactions.
@nl
prefLabel
Immunotherapy in elderly trans ...... significant drug interactions.
@en
Immunotherapy in elderly trans ...... significant drug interactions.
@nl
P2860
P1433
P1476
Immunotherapy in elderly trans ...... significant drug interactions.
@en
P2093
Dirk R J Kuypers
P2860
P304
P356
10.2165/11316480-000000000-00000
P577
2009-01-01T00:00:00Z
P5875
P6179
1025688462